Article Link: FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer April 4, 2019 — ...
FDA Approves Avaclyr (acyclovir ophthalmic ointment) for the Treatment of Herpetic Keratitis
Article Link: FDA Approves Avaclyr (acyclovir ophthalmic ointment) for the Treatment of Herpetic Keratitis NEW YORK–(BUSINESS WIRE) April...
FDA Approves the Reintroduction of Zelnorm (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in Women Under 65
Article Link: FDA Approves the Reintroduction of Zelnorm (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in Women Under 65 &#...
FDA Approves Asceniv (immune globulin intravenous, human) for Primary Humoral Immunodeficiency
Article Link: FDA Approves Asceniv (immune globulin intravenous, human) for Primary Humoral Immunodeficiency RAMSEY, N.J. and BOCA RATON,...
FDA Approves Duaklir Pressair (aclidinium bromide and formoterol fumarate) for Maintenance Treatment of Chronic Obstructive Pulmonary Disease
Article Link: FDA Approves Duaklir Pressair (aclidinium bromide and formoterol fumarate) for Maintenance Treatment of Chronic Obstructive Pulmonary Di...
FDA Approves Mavenclad (cladribine) Tablets for Multiple Sclerosis
Article Link: FDA Approves Mavenclad (cladribine) Tablets for Multiple Sclerosis March 29, 2019 — The U.S. Food and Drug Administra...
FDA Approves Cimzia (certolizumab pegol) for the Treatment for Non-Radiographic Axial Spondyloarthritis
Article Link: FDA Approves Cimzia (certolizumab pegol) for the Treatment for Non-Radiographic Axial Spondyloarthritis Brussels, Belgium –...
FDA Approves Jatenzo (testosterone undecanoate) for Certain Forms of Hypogonadism
Article Link: FDA Approves Jatenzo (testosterone undecanoate) for Certain Forms of Hypogonadism March 27, 2019 — The U.S. Food and ...
FDA Approves Mayzent (siponimod) for Secondary Progressive Multiple Sclerosis
Article Link: FDA Approves Mayzent (siponimod) for Secondary Progressive Multiple Sclerosis Basel, March 27, 2019 – Novartis today ...
FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Article Link: FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea D...
